Nitroaromatic musks, including musk ketone (MK; 2,6-dimethyl-3,5-dinitro-4-f-butylacetophenone), are chemicals used as perfume ingredients in household products, cosmetics, and toiletries. Musk xylene (MX; l,3,5-trinitro-2-r-butylxylene), another nitromusk, is not genotoxic but has been reported to produce mouse liver tumors in a chronic bioassay. In addition, MX has been shown to both induce and inhibit mouse liver cytochrome P450 2B (CYP2B) isozymes. The ability of MX to inhibit CYP2B enzyme activity is attributable to inactivation of the enzyme by a specific amine metabolite. MK is structurally similar to MX, but lacks the nitro substitution that is reduced to the inactivating amine metabolite. Therefore, we hypothesized that MK would induce, but not inhibit, CYP2B isozymes. To test this hypothesis, and to evaluate the effects of MK on mouse liver cytochrome P450 enzymes, two sets of experiments were performed. To evaluate the ability of MK to induce cytochromes P450, mice were dosed daily by oral gavage at dosages ranging from 5 to 500 mg/ kg MK for 7 days. This treatment resulted in a pleiotropic response in mouse liver, including increased liver weight, increased total mkrosomal protein, and centrilobular hepatocellular hypertrophy. At the highest dose tested, MK caused a 28-fold increase in CYP2B enzyme activity and a small (approximately 2-fold) increase in both cytochromes P450 1A and 3A (CYP1A and CYP3A) enzyme activities over control levels. Protein and mRNA analyses confirmed the relative levels of induction for CYP2B, CYP1A, and CYP3A. In addition, the no-observable-effect level (NOEL) for CYP2B induction by MK was 20 mg/kg. To evaluate the ability of MK to inhibit phenobarbitalinduced CYP2B activity, mice were given 500 ppra phenobarbital (PB) in the drinking water for 5 days to induce CYP2B isozymes, followed by a single equimolar (0.67 mmol/kg) oral gavage dose of either MK (198 mg/kg) or MX (200 mg/kg), and microsomes were prepared 18 h later. While MX inhibited more than 90% of the PBinduced CYP2B activity in the microsomes, MK caused only a small (about 20%) reduction in PB-induced CYP2B enzyme activity. These results indicate that, like MX, MK is a PB-type inducer of mouse liver CYP2B isozymes, but unlike MX, MK does not effectively inhibit PB-induced CYP2B enzyme activity. s> vxn Soday of Toxi col ogy.
Nitroaromatic musks, including musk ketone (MK; 2,6-dimethyl-3,5-dinitro-4-f-butylacetophenone), are chemicals used as perfume ingredients in household products, cosmetics, and toiletries. Musk xylene (MX; l,3,5-trinitro-2-r-butylxylene), another nitromusk, is not genotoxic but has been reported to produce mouse liver tumors in a chronic bioassay. In addition, MX has been shown to both induce and inhibit mouse liver cytochrome P450 2B (CYP2B) isozymes. The ability of MX to inhibit CYP2B enzyme activity is attributable to inactivation of the enzyme by a specific amine metabolite. MK is structurally similar to MX, but lacks the nitro substitution that is reduced to the inactivating amine metabolite. Therefore, we hypothesized that MK would induce, but not inhibit, CYP2B isozymes. To test this hypothesis, and to evaluate the effects of MK on mouse liver cytochrome P450 enzymes, two sets of experiments were performed. To evaluate the ability of MK to induce cytochromes P450, mice were dosed daily by oral gavage at dosages ranging from 5 to 500 mg/ kg MK for 7 days. This treatment resulted in a pleiotropic response in mouse liver, including increased liver weight, increased total mkrosomal protein, and centrilobular hepatocellular hypertrophy. At the highest dose tested, MK caused a 28-fold increase in CYP2B enzyme activity and a small (approximately 2-fold) increase in both cytochromes P450 1A and 3A (CYP1A and CYP3A) enzyme activities over control levels. Protein and mRNA analyses confirmed the relative levels of induction for CYP2B, CYP1A, and CYP3A. In addition, the no-observable-effect level (NOEL) for CYP2B induction by MK was 20 mg/kg. To evaluate the ability of MK to inhibit phenobarbitalinduced CYP2B activity, mice were given 500 ppra phenobarbital (PB) in the drinking water for 5 days to induce CYP2B isozymes, followed by a single equimolar (0.67 mmol/kg) oral gavage dose of either MK (198 mg/kg) or MX (200 mg/kg), and microsomes were prepared 18 h later. While MX inhibited more than 90% of the PBinduced CYP2B activity in the microsomes, MK caused only a small (about 20%) reduction in PB-induced CYP2B enzyme activity. These results indicate that, like MX, MK is a PB-type inducer of mouse liver CYP2B isozymes, but unlike MX, MK does not effectively inhibit PB-induced CYP2B enzyme activity. s> vxn Soday of Toxi col ogy.
Synthetic nitroaromatic musks (nitromusks) are ingredients in perfume formulations used in a variety of products including household chemicals, cosmetics, and toiletries. Musk xylene (MX; l,3,5-trinitro-2-r-butylxylene) and musk ketone (MK; 2,6-dimethyl-3,5-dinitro-4-r-butylacetophenone) are structurally very similar ( Fig. 1 ) and have been widely used. Concern has been raised over the risk nitromusks pose to human health because MX treatment caused a high incidence of mouse liver tumors in a chronic bioassay (Maekawa et al, 1990) . In addition, nitromusks have been detected in the environment, including freshwater fish (Yamagishi etal, 1981) , and in human tissues, including fat and breast milk (Rimkus and Wolf, 1993; Rimkus et al, 1994) .
Despite producing liver tumors in mice, MX was uniformly negative in a battery of in vitro genotoxicity tests (Api et al, 1996a) . Subsequent to the bioassay, additional research has been conducted to determine the biochemical effects of MX in rats and mice. MX was initially described as a novel specific inducer of hepatic cytochrome P450 1A2 (CYP1A2) enzyme activity in the rat (Iwata et al., 1992 (Iwata et al., , 1993a . However, recent work in mice has indicated that MX caused a coordinated pleiotropic response in the liver, including potent induction of hepatic cytochrome P450 2B (CYP2B) isozymes (Lehman-McKeeman et al, 1995 , 1997a IARC, 1996) . Although MX induced CYP2B protein and mRNA in mice in a dose-dependent manner, it caused no concomitant increase in CYP2B enzyme activity, indicating that MX inhibits CYP2B isozymes in vivo. In vitro, however, parent MX did not significantly inhibit CYP2B enzyme activity (Lehman-McKeeman et al, 1997a) , suggesting that a metabolite of MX was responsible for the inhibition observed in vivo. A common metabolic pathway for nitroaromatics is nitroreduction by gut microflora to aromatic amines. Treatment of mice with broad spectrum antibiotics to depress gut microflora eliminated the inhibition of phenobarbital-induced CYP2B activity by MX in vivo, indicating that gut microflora plays a role in formation of the CYP2B-inhibiting species of MX (Lehman-McKeeman et 0272-0590/97 $25. ai, 1997a,b). These results were explained when an amine metabolite of MX, p-NH 2 -MX, was identified as a mechanism-based inactivator of mouse CYP2B isozymes (Lehman-McKeeman et al, 1997a,b) . Thus, reduction of the nitro group para to the f-butyl substitution on MX results in CYP2B inactivation.
Although MK has been used widely as a fragrance ingredient, neither its biochemical effects nor carcinogenic potential has been extensively studied to date. MK is structurally identical to MX except that it possesses an acetyl group, instead of a nitro function, para to the r-butyl substitution (Fig. 1) . In addition, MK has been shown to be uniformly negative in a battery of genetic toxicity tests (Api et ai, 1996b) . Based on the overall structural similarity of MK to MX, we hypothesized that MK would induce CYP2B isozymes in mouse liver in a manner similar to MX and phenobarbital (PB). However, because nitroreduction of MK cannot yield a /7-NH 2 -metabolite, we hypothesized that MK would not inhibit CYP2B isozymes in mouse liver in a manner similar to MX. To test these hypotheses, the induction and inhibition of cytochrome P450 enzymes by MK were evaluated.
METHODS
Animals. Male B6C3F1 (20-25 g) mice were obtained from Charles River Laboratories (Portage, MI). Mice were housed in a temperatureand humidity-controlled environment, acclimated for at least 4 days, and randomized into treatment groups based on body weight. Unless otherwise noted, mice were housed in shoebox cages by treatment groups and were allowed rodent chow (Ralston-Purina, St. Louis, MO) and water ad libitum throughout the study.
Chemicals. MX was supplied by Polarome (Jersey City, NJ) and MK was supplied by Givaudan-Roure Corp. (Dubendorf, Switzerland). MX and MK were essentially 100 and 99% pure, respectively, as determined by gas chromatographic-mass spectral analysis. Dose solutions were prepared in corn oil (Mazola; Best Foods, Englewood Cliffs, NJ) with sonication and were administered by gavage. PB was supplied by Sigma Chemicals (St Louis, MO). The PB dose solution was prepared in a distilled, deionized water vehicle and was administered ad libitum in the drinking water. All other chemicals and reagents were standard laboratory grade from Sigma Chemical Co. or J. T. Baker (Phillipsburg, NJ), unless otherwise noted.
Induction of cytochromes P450 by MK. Mice (n = 7/group) were dosed daily by oral gavage for 7 consecutive days with 0, 5, 10, 20, 50, 100, 200, or 500 mg/kg MK at a 20 ml/kg dosing volume. Control animals received corn oil at the same dosing volume. Mice were food-fasted overnight and were necropsied approximately 24 h after the last dose. For each treatment group, five mice were used for liver histology and microsome preparation. Livers were removed and weighed, a portion was placed in buffered formalin for histology, and the remainder was used for isolation of the microsomal fraction. The remaining two mice/group were used for mRNA analyses. For these mice, livers were flash-frozen in liquid nitrogen and stored at -80°C pending analyses.
Inhibition of PB-induced CYP2B activity by MK.
Mice received 500 ppm PB in the drinking water ad libitum for 4 days to induce CYP2B isozymes. On the afternoon of the fourth day of PB treatment, mice (n = 5/group) were gavaged with either com oil (control) or MX or MK (0.67 mmol/kg each) at a 10 ml/kg dosing volume, after which they were foodfasted but continued to receive PB in the drinking water. The liver microsomal fraction was isolated 18 h after dosing the nitromusk.
Preparation and general analysis of microsomes. The microsomal fraction of the liver was isolated by differentia] centrifugarjon according to procedures outlined by Guengerich (1989) . Microsomes were stored at -80°C when not in use. Microsomal total protein content was determined by the method of Bradford (1976) with bovine serum albumin as the standard. Microsomal total P450 content was determined by the method of Omura and Sato (1964) using the carbon monoxide difference spectrum of dithionitereduced microsomes with an extinction coefficient of 91 mM" 1 cm" 1 .
Microsomal enzyme assays. CYP1A and CYP2B enzyme activities were determined by fluorometric analysis of o-dealkylation of phenoxazone ethers as described by Burke et aL (1985) . For CYP1A isozymes, ethoxyresorufin and methoxyresorufin were used as substrates and for CYP2B isozymes, pentoxyresorufin was used as a substrate. EROD (ethoxyresorufin o-dealkylation), MROD (methoxyresorufin o-dealkylation), and PROD (pentoxyresorufin o-dealkylation) reactions were carried out at 37°C with a substrate concentration of either 5 /*M (PROD and MROD) or 2 /JM (EROD). Linear reactions were monitored over a 2-min interval using a fluorometer (Perkin-Elmer LS50B, Norwalk, CT).
CYP3A enzyme activity was determined by a spectrophotometric assay that measures the n-demethylation of erythromycin as described by Wrighton et al. (1985) . This reaction is quantified as the formation of formaldehyde as described by Nash (1953) . ERND (erythromycin n-demethylation) reactions were carried out at 37°C for 10 min with a substrate concentration of 500 fj.M. Color was developed by incubation with Nash reagent and absorbance was quantified at 412 nm using a Beckman Instruments (Fullerton, CA) DU-650 spectrophotometer.
Immunoblotting.
Microsomal cytochrome P450 protein levels were estimated by densitometry of Western blots. Unless otherwise noted, all reagents were electrophoresis grade and were supplied by Bio-Rad (Hercules, CA). For each gel, 10 /jg microsomal protein was separated by SDS-PAGE as described by Laemmli (1970) on 7.5% polyacrylamide gels (5X10 cm) and proteins were transferred electrophoretically to nitrocellulose membranes. Membranes were blocked with 5% nonfat dried milk for 1.5 h and then incubated overnight at 4°C in a 1/2500 dilution of primary antibody in the same solution. Primary antibodies used were all polyclonal rabbit anti-rat liver cytochrome P450 antibodies (Xenotech, Kansas City, KS) for detection of CYP2B1, CYP1A1 and 1A2, and CYP3A1, respectively. Due to die high homology of these proteins between rat and mouse, these antibodies readily cross-react witii the major mouse isoforms of CYP2B, 1A, and 3A. For each dose group, at least two individual samples were analyzed. Proteins were visualized colorimetrically with an alkaline phosphatase-con-jugated goat anti-rabbit IgG secondary antibody. Digital images of blots were created with a scanning densitometer (Howtek, Hudson, NH). mRNA measurements. mRNA levels were determined by standard procedures for total RNA isolation, slot blotting, and hybridization with antisense oligonucleotides. Unless otherwise noted, all reagents were molecular biology grade and were supplied by Bio-Rad. Total RNA was isolated from approximately 100 mg flash-frozen liver tissue using GibcoBRL Trizol reagent (Life Technologies, Gaithersburg, MD) according to manufacturer's instructions. RNA concentrations of the isolates were estimated by spectrophotometric analysis. Total RNA samples were applied directly to nylon membranes which were then UV cross-linked (125 mj) and prehybridized for 5 h in a solution of 6x SSPE, 5x Denhardt's reagent, 0.1% SDS, and 100 /ig/ml fragmented salmon sperm DNA (Pharmacia Biotech, Uppsala, Sweden) at either 50°C (for CYP2B10 and CYP3A11/13) or 52°C (for CYP1A2). Hybridization was performed overnight, at the same temperature as prehybridization, in a fresh aliquot of the prehybridization solution with the addition of 10% dextran sulfate and the appropriate n P-labeled oligodeoxynucleotide probe. After hybridization, membranes were rinsed twice for 10 min each time in 5x SSC/0.1% SDS and then once for 10 min each in 0.5x SSC/0.1% SDS followed by 0.1X SSC/0.1% SDS. All rinses were performed at 50°C. mRNA was detected as bound radioactivity with an electronic autoradiography system (Instantlmager, Packard Instruments, Meridian, CT) and results were obtained as cpm/hybrid.
For detection of CYP2B10 mRNA, a 20-mer oligodeoxynucleotide, 5'-TCCTTGAAGGTTGGCTCAAAC-3', originally described by Adams et al. (1993) , was used which corresponds to nucleotides 281 to 300 of the Cyp2blO cDNA (Noshiro et al., 1988) . For detection of CYP1A2 mRNA, a 20-mer oligodeoxynucleotide, 5'-CCACTGAAGGGCAGGGGCTG-3', was used which corresponds to a 5' region including the transcription start site of the Cypla2 cDNA (Kimura et al., 1984) . For detection of CYP3A11/ 13 mRNA, a 22-mer oligodeoxynucleotide, 5'-CAGAGGTTTGGGCCC-AGGAATT-3', was used which corresponds to the nucleotides encoding amino acids 167 to 173 of Cyp3all/13 (Yanagimoto et al, 1992) . For detection of 18s rRNA as a housekeeping gene, a 20-mer oligodeoxynucleotide, 5'-CACCTCTAGCGCCGCAATAC-3", originalJy described by Hassett et al. (1990) , was used. All oligomers were made using a DNA synthesizer (Applied Biosystems, Forest City, CA) and labeled at the 5' terminus with [
32 P]dATP (Amersham Life Sciences, Arlington Heights, IL) catalyzed by T 4 polynucleotide kinase (Pharmacia Biotech). After labeling, free [ 32 P]-dATP was removed from the 10-pmol oligomer preparation using Bio-Spin 6 columns (Bio-Rad). The resulting specific activities for these probes were typically 1-2 fid per picomole. Specificity of the oligodeoxynucleotide probes for their target mRNAs was confirmed using total RNA samples isolated from appropriate positive and negative control treatments.
Statistical analysis. Data were analyzed for statistical significance by analysis of variance (ANOVA) followed by a multiple comparison test (Fischer's PLSD) using StatView 4.1 (Abacus Concepts, Berkeley, CA). For statistical comparisons, a 5% significance level (p < 0.05) was used.
RESULTS
To determine whether MK was a microsomal enzyme inducer, mice were dosed orally for 7 consecutive days with MK over a dosage range of 5 to 500 mg/kg. Table 1 summarizes the results of the general hepatic effects of MK treatment. A dose-related increase in liver to body weight ratio and microsomal total protein was observed at dosages above 20 mg/kg MK. At the highest dosage tested, a 50% increase in relative liver weight was observed, while total micTOSomal protein increased 2-fold relative to control. Total cytochrome 1.01 ± 0.03 1.05 ± 0.10 1.26 ± 0.02* 1.24 ± 0.08* 1.61 ± 0.05* 1.66 ± 0.05* 1.78 ± 0.14* 1.76 ± 0.07* " Animals were dosed for 7 days by oral gavage and the results represent the means ± SE of four or five mice per group. * Liver to body weight ratio, with liver weight expressed as a percentage of total body weight * Denotes statistical difference from reported control value at p < 0.05.
P450 content was increased at dosages of 10 mg/kg MK and higher, reaching about a 50% increase at 500 mg/kg. MK treatment also caused histological changes in the liver, primarily centrilobular hepatocellular hypertrophy. At the highest dosage, there was marked panlobular hepatocellular hypertrophy (Fig. 2) . Collectively, these liver effects are consistent with those associated with PB-like microsomal enzyme inducers. Induction of CYP2B, CYP1 A, and CYP3A enzyme activities by MK is shown in Figs. 3, 4 , and 5, respectively. MK treatment increased CYP2B enzyme activity over control levels at dosages above 20 mg/kg, and at the highest dosage tested CYP2B enzyme activity was increased 28-fold. In contrast, MK treatment increased CYPlA-catalyzed EROD and MROD activities over control levels at dosages above 100 and 20 mg/kg MK, respectively. At the highest dosage tested, EROD and MROD activities increased approximately 2-and 4-fold, respectively. MK treatment also increased CYP3A enzyme activity over control levels at dosages of 20 mg/kg and higher. As with CYP1 A, at the highest dosage studied, CYP3A activity increased about 2-fold relative to control levels. Figure 6 shows the results of Western blots to determine CYP2B, CYP1A, and CYP3A immunoreactive protein levels in liver microsomes from MK-treated mice. This figure demonstrates that MK treatment caused a dose-related and the largest overall increase in immunoreactive CYP2B protein levels. At the highest dose of MK, the immunoreactive protein levels for all isozymes were increased in a manner consistent with the relative increases in respective enzyme activity. Figure 7 shows the results of slot blots to determine CYP2B10, CYP1A2, and CYP3A11/13 mRNAs in MKtreated mice. When normalized for RNA loading by compar- ison with corresponding 18s rRNA levels, these blots indicate that MK treatment was most effective at increasing the CYP2B10 mRNA with much smaller increases in CYP1A2 or CYP3A11/13 mRNAs. These results demonstrate that MK treatment increased the mRNA levels in a manner consistent with the protein and enzyme activity increases observed for each isozyme.
To determine whether MK inhibited CYP2B isozymes in vivo in a manner similar to MX, a single equimolar dose of either MK or MX was administered to PB-induced mice and CYP2B enzyme activity and protein levels were determined 18 h later. Table 2 summarizes the results of this experiment. In the PB-induced control group, PROD activity was increased approximately 25-fold over values typically observed in uninduced mice. Acute MX treatment reduced PBinduced CYP2B enzyme activity by more than 90%. In contrast, an equimolar dosage of MK reduced PB-induced CYP2B enzyme activity by approximately 20%. With both MX and MK, no decrease in CYP2B immunoreactive protein levels from those of PB-induced controls was observed, despite the observation of decreased CYP2B enzyme activity (results not shown).
DISCUSSION
The goal of the present work was to determine whether MK, a nitromusk structurally similar to MX, caused biochemical effects comparable to those observed with MX. The results indicate that MK is an effective inducer of CYP2B isozymes in mouse liver, and as with MX the induction of CYP2B isozymes by MK is pretranslationaJ, likely occurring by transcriptional activation of the Cyp2blO gene. MK treatment also increased liver weight, produced histological evidence of centrilobular hepatocellular hypertrophy, The effects of MK on CYP2B enzyme activity in mouse liver. MK treatment resulted in a dose-related increase in CYP2B enzyme activity, with a NOEL of 20 mg/kg. At the highest dose, CYP2B enzyme activity was increased approximately 28-fold over control levels. Reported value represents the mean ± SE of five animals per dose group. *Denotes statistical difference from reported control value at p < 0.05. and increased the yield of total microsomal protein, results that are routinely associated with induction of CYP2B isozymes (Lubet et al, 1989; Whysner et al., 1996) . With MK treatment, small changes in CYP1A and CYP3A enzyme activities were also observed, but these effects were consistent with the induction of these isozymes observed in mice following exposure to PB (Parkinson et al, 1992) or MX (Lehman-McKeeman et al, 1997a) . Collectively, the results establish that, as with MX, MK is a PB-like inducer of cytochrome P450 enzymes in mice.
Given the general similarity in the hepatic effects of MK and MX, a notable feature of these chemicals is that their biochemical and toxicological properties are readily distinguished from other nitroaromatic compounds. For example, there is little or no evidence to suggest that other nitroaromatic chemicals induce CYP2B isozymes (Decad et al., 1979) . Furthermore, some nitroaromatic compounds, particularly 2,6-dinitrotoluene, are hepatotoxic in rats, a response seen with both in vitro (Spanggord et al., 1990) and in vivo studies (Rickert et al., 1984; Dunnick et al., 1994) . In contrast, there is no evidence of hepatotoxicity in rats or mice from in vivo or in vitro exposures to MK or MX (Api et al., I996a,b; Maekawa et al., 1990; Iwata et al., 1993a) .
Another characteristic of most nitroaromatic chemicals, including the nitromusks, is that reduction of nitro functions to their corresponding aromatic amines is a primary metabolic pathway. Aromatic amines are substrates for and are activated by CYP1A2 isozymes (Hammons et al, 1985; Butler et al, 1989) , and several aromatic amines have also been shown to selectively induce CYP1A2 in rodents Degawa et al, 1995) . Previously published data in rats (Iwata et al., 1992 (Iwata et al., , 1993a and in vitro experiments (Mersch-Sundermann et al, 1996) have concluded that both MK and MX induce CYP1A, particularly CYP1A2 isozymes. Although this response would be consistent with the general action of aromatic amines, in all cases the authors failed to measure CYP2B isozyme and protein levels. Furthermore, as seen with MK treatment, changes in CYP1A isozymes occur at higher dosages than those required to induce CYP2B isozymes, and the magnitude of the change in CYP1A isozymes is much smaller than the increase in CYP2B levels. Thus, any effect on CYP1A isozymes is minor when compared to the induction of CYP2B isozymes.
Although MK is similar to MX with respect to its enzyme induction properties, it is distinguished from MX in its ability to inhibit CYP2B isozymes. The difference in CYP2B inhibition capacity likely results from the minor structural difference between MK and MX: MK possesses an acetyl rather than a nitro group para to the f-butyl substitution. Therefore, nitroreduction of MK can only yield one amine metabolite which is oriented ortho to the f-butyl group. In vitro, only the p-NH 2 metabolite of MX has been shown to inactivate CYP2B isozymes (Lehman-McKeeman et al., 1997b) . In addition, data from rats (Minegishi et al., 1991) and mice (Lehman-McKeeman, unpublished data) Representative slot blots showing the effects of MK on CYP2B, CYPIA, and CYP3A mRNA levels in mouse liver. MK treatment resulted in a dose-related increase in CYP2B10 mRNA levels and also increased CYP1A2 and CYP3A11/13 mRNA levels at the higher dosages. Total RNA was loaded at 5-10 or I-2 /jg per slot for detection of either specific cytochromes P450 mRNA or 18s rRNA, respectively. Each slot represents a single animal from the respective dose group. rodents, with only minimal formation of the o-NH 2 metabolite, likely due to steric hindrance at the ortho position by the adjacent r-butyl moiety. Regardless of whether an o-NH 2 metabolite is responsible for the slight inhibition of PBinduced CYP2B activity by MK, its ability to inhibit CYP2B isozyme function is apparently of little biological significance since MK-induced increases in CYP2B enzyme activity were generally consistent with increased CYP2B protein and mRNA levels.
Based on the dose response for CYP2B isozyme induction seen with MK treatment, it is unlikely that human exposure to MK will produce similar effects on P450 enzymes. The no-effect level for induction by MK in mice was 20 mg/kg, a dosage which is at least 100 times greater than the estimated maximal human exposure to this perfume ingredient (unpublished data). Since CYP2B induction has been correlated to liver tumor promotional activity in rodents (Nims et al., 
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" Mice received 500 ppm PB in the drinking water ad libitum for 4 days to induce CYP2B enzymes, followed by a gavage treatment with either com oil (CO) or 0.67 mmol/kg nitro musk (approximately 200 mg/kg). Microsomes were prepared 18 h later. The results represent the means ± SE of five mice per group. * CYP2B enzyme activity in microsomes was measured by the o-dealkylation of pentoxyresorufin (PROD).
1987; Lubet et ah, 1989; Williams et ai, 1996) , it has been suggested that MX-induced liver tumors may arise by a mechanism similar to PB (Lehman-McKeeman et ai, 1997a) . The present data portend that MK might also produce liver tumors in mice in a similar manner. However, it is widely accepted that liver tumors in rodents resulting from nongenotoxic chemicals shown to be microsomal enzyme inducers are not predictive of a similar risk to humans (Whysner et ai, 1996; IARC, 1985) .
In summary, we have demonstrated that MK is a PB-like inducer of hepatic cytochrome P450 enzymes in the mouse. In this manner, MK is similar to MX, and this effect distinguishes these nitromusks from other nitroaromatic chemicals. Conversely, MK is different from MX because it does not inhibit CYP2B isozymes, thereby illustrating how minor structural differences can yield marked differences in biochemical effects.
